tiprankstipranks
Advertisement
Advertisement

IMDX Stock Latest News

Insight Molecular Diagnostics: Buy Rating Reiterated on Growing Clinical Adoption of Donor-Derived cfDNA Testing and Unchanged $9 Price Target
RatingsInsight Molecular Diagnostics: Buy Rating Reiterated on Growing Clinical Adoption of Donor-Derived cfDNA Testing and Unchanged $9 Price Target
8h ago
IMDX
Michael Matson Reiterates Buy on IMDX, Citing Regulatory Progress, GraftAssure Platform Expansion, and Solid Cash Runway Ahead of Expected 2026 De Novo Approval
PremiumRatings
Michael Matson Reiterates Buy on IMDX, Citing Regulatory Progress, GraftAssure Platform Expansion, and Solid Cash Runway Ahead of Expected 2026 De Novo Approval
7d ago
IMDX
Insight Molecular Nears FDA Authorization for GraftAssureDx Assay
PremiumCompany Announcements
Insight Molecular Nears FDA Authorization for GraftAssureDx Assay
8d ago
8K
IMDX
Insight Molecular Diagnostics reports Q2 EPS (31c), consensus (23c)
PremiumThe Fly
Insight Molecular Diagnostics reports Q2 EPS (31c), consensus (23c)
8d ago
IMDX
IMDX Earnings this Week: How Will it Perform?
PremiumPre-Earnings
IMDX Earnings this Week: How Will it Perform?
10d ago
IMDX
GALACTIC Trial: IMDX Advances Non‑Invasive Kidney Transplant Monitoring
PremiumCompany AnnouncementsGALACTIC Trial: IMDX Advances Non‑Invasive Kidney Transplant Monitoring
19d ago
IMDX
Insight Molecular Diagnostics highlights Lancet study on GraftAssure assay
Premium
The Fly
Insight Molecular Diagnostics highlights Lancet study on GraftAssure assay
26d ago
IMDX
Insight Molecular Diagnostics Shareholders Back Board and Incentive Plan
Premium
Company Announcements
Insight Molecular Diagnostics Shareholders Back Board and Incentive Plan
2M ago
8K
IMDX
Insight Molecular Diagnostics Balances Progress and Cash Burn
PremiumCompany Announcements
Insight Molecular Diagnostics Balances Progress and Cash Burn
3M ago
IMDX
OncoCyte’s Earnings Call Maps Risky Path to Launch
PremiumCompany Announcements
OncoCyte’s Earnings Call Maps Risky Path to Launch
3M ago
IMDX
Insight Molecular Diagnostics Maintained at Buy as GraftAssure Platform Gains Traction; $9 Price Target Reaffirmed
PremiumRatings
Insight Molecular Diagnostics Maintained at Buy as GraftAssure Platform Gains Traction; $9 Price Target Reaffirmed
3M ago
IMDX
Insight Molecular Corrects Bylaws Disclosure in Annual Report
PremiumCompany Announcements
Insight Molecular Corrects Bylaws Disclosure in Annual Report
4M ago
8K
IMDX
Insight Molecular Diagnostics: Building Momentum with GraftAssure Platform and Favorable Risk‑Reward Supporting Buy Rating
PremiumRatingsInsight Molecular Diagnostics: Building Momentum with GraftAssure Platform and Favorable Risk‑Reward Supporting Buy Rating
4M ago
IMDX
OncoCyte Earnings Call: GraftAssureDx Drives Pivot
Premium
Company Announcements
OncoCyte Earnings Call: GraftAssureDx Drives Pivot
5M ago
IMDX
Buy Rating on IMDX Driven by Strong GraftAssure Traction, Upcoming FDA Catalyst, and Solid Balance Sheet
Premium
Ratings
Buy Rating on IMDX Driven by Strong GraftAssure Traction, Upcoming FDA Catalyst, and Solid Balance Sheet
5M ago
IMDX
Insight Molecular Diagnostics submits GraftAssureDx for FDA review
PremiumThe Fly
Insight Molecular Diagnostics submits GraftAssureDx for FDA review
5M ago
IMDX
Insight Molecular Diagnostics reports Q4 EPS (27c) vs. (28c) last year
PremiumThe Fly
Insight Molecular Diagnostics reports Q4 EPS (27c) vs. (28c) last year
5M ago
IMDX
OCX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
OCX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
5M ago
IMDX
Insight Molecular Diagnostics highlights publication of study on GraftAssure
PremiumThe Fly
Insight Molecular Diagnostics highlights publication of study on GraftAssure
5M ago
IMDX
Insight Molecular Diagnostics completes milestones advancing GraftAssureDx
PremiumThe FlyInsight Molecular Diagnostics completes milestones advancing GraftAssureDx
6M ago
IMDX
Insight Molecular Diagnostics: GraftAssureIQ Validation and Hospital Adoption Set Up 2026 as a Growth Inflection Year
Premium
Ratings
Insight Molecular Diagnostics: GraftAssureIQ Validation and Hospital Adoption Set Up 2026 as a Growth Inflection Year
6M ago
IMDX
Insight Molecular Diagnostics Signs Quest Specimen Collection Agreement
Premium
Company Announcements
Insight Molecular Diagnostics Signs Quest Specimen Collection Agreement
6M ago
8K
IMDX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >